Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation

Authors: Chongkai Wang MD, MS1 and Marwan Fakih MD1
View More View Less
  • 1 Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California

Dual HER2-targeted therapy has been associated with clinical responses and prolonged progression-free survival and overall survival in RAS-wild type HER2-amplified colorectal cancer (CRC). However, no clinical benefits have been reported in patients with CRC with HER2 mutations. Activated HER2 mutations have been largely deemed resistant to trastuzumab and to dual HER2 targeting. This report describes a patient with metastatic CRC with concurrent HER2 amplification and a HER2 S310F mutation, which is an active mutation located in the extracellular dimerization domain of HER2. Treatment with trastuzumab + lapatinib resulted in an excellent response that lasted for 10 months. Upon disease progression, treatment with the antibody–drug conjugate trastuzumab–deruxtecan resulted in a short-lived response. This is the first case report of successful HER2 targeting in metastatic CRC with concurrent HER2 amplification and a HER2 S310F mutation.

Submitted December 15; 2020; revision received February 1; 2021; accepted for publication February 2; 2021.

Disclosures: Dr. Fakih has disclosed receiving honoraria from Amgen; receiving grant/research support from AstraZeneca, Amgen, and Novartis; serving as a scientific advisor for Amgen, Array, Bayer, and Pfizer; and serving on a speakers’ bureau for Amgen and Guardant Health. Dr. Wang has disclosed not receiving any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Marwan Fakih, MD, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010. Email: mfakih@coh.org
  • 1.

    Richman SD, Southward K, Chambers P, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol 2016;238:562570.

    • Search Google Scholar
    • Export Citation
  • 2.

    Bai J, Gao J, Mao Z, et al. Genetic mutations in human rectal cancers detected by targeted sequencing. J Hum Genet 2015;60:589596.

  • 3.

    Ingold Heppner B, Behrens HM, Balschun K, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer 2014;111:19771984.

  • 4.

    Raghav K, Loree JM, Morris JS, et al. Validation of HER2 amplification as a predictive biomarker for anti–epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. JCO Precis Oncol 2019;3:113.

    • Search Google Scholar
    • Export Citation
  • 5.

    Bregni G, Sciallero S, Sobrero A. HER2 amplification and anti-EGFR sensitivity in advanced colorectal cancer. JAMA Oncol 2019;5:605606.

    • Search Google Scholar
    • Export Citation
  • 6.

    Martin V, Landi L, Molinari F, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer 2013;108:668675.

    • Search Google Scholar
    • Export Citation
  • 7.

    Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011;1:508523.

    • Search Google Scholar
    • Export Citation
  • 8.

    Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016;17:738746.

    • Search Google Scholar
    • Export Citation
  • 9.

    Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 2019;20:518530.

    • Search Google Scholar
    • Export Citation
  • 10.

    Benson AB III, Venook AP, Al-Hawary MM, et al. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 2.2021. Accessed February 8, 2021. To view the most recent version, visit NCCN.org

  • 11.

    Siena S, Bartolomeo MD, Raghav KPS, et al. A phase II, multicenter, open-label study of trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): DESTINY-CRC01 [abstract]. J Clin Oncol 2020;38(Suppl):Abstract 4000.

    • Search Google Scholar
    • Export Citation
  • 12.

    Ross JS, Fakih M, Ali SM, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer 2018;124:13581373.

    • Search Google Scholar
    • Export Citation
  • 13.

    Kavuri SM, Jain N, Galimi F, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov 2015;5:832841.

  • 14.

    Ben-Baruch NE, Bose R, Kavuri SM, et al. HER2-mutated breast cancer responds to treatment with single-agent neratinib, a second-generation HER2/EGFR tyrosine kinase inhibitor. J Natl Compr Canc Netw 2015;13:10611064.

    • Search Google Scholar
    • Export Citation
  • 15.

    Xu X, De Angelis C, Burke KA, et al. HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer. Clin Cancer Res 2017;23:51235134.

    • Search Google Scholar
    • Export Citation
  • 16.

    Nagano M, Kohsaka S, Ueno T, et al. High-throughput functional evaluation of variants of unknown significance in ERBB2. Clin Cancer Res 2018;24:51125122.

    • Search Google Scholar
    • Export Citation
  • 17.

    Cocco E, Javier Carmona F, Razavi P, et al. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2). Sci Signal 2018;11:eaat9773.

    • Search Google Scholar
    • Export Citation
  • 18.

    Zuo WJ, Jiang YZ, Wang YJ, et al. Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer. Clin Cancer Res 2016;22:48594869.

    • Search Google Scholar
    • Export Citation
  • 19.

    Pahuja KB, Nguyen TT, Jaiswal BS, et al. Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell 2018;34:792806.e5.

    • Search Google Scholar
    • Export Citation
  • 20.

    Ou SI, Schrock AB, Bocharov EV, et al. HER2 transmembrane domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib. J Thorac Oncol 2017;12:446457.

    • Search Google Scholar
    • Export Citation
  • 21.

    Greulich H, Kaplan B, Mertins P, et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci USA 2012;109:1447614481.

    • Search Google Scholar
    • Export Citation
  • 22.

    Bose R, Kavuri SM, Searleman AC, et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013;3:224237.

    • Search Google Scholar
    • Export Citation
  • 23.

    Siravegna G, Sartore-Bianchi A, Nagy RJ, et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin Cancer Res 2019;25:30463053.

    • Search Google Scholar
    • Export Citation
  • 24.

    Strickler JH, Zemla T, Ou FS, et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial [abstract]. Ann Oncol 2019;30(Suppl 5):Abstract 527PD.

    • Search Google Scholar
    • Export Citation
  • 25.

    Nakamura Y, Okamoto W, Kato T, et al. TRIUMPH: primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): a GOZILA sub-study [abstract]. Ann Oncol 2019;30(Suppl 5):Abstract 526PD.

    • Search Google Scholar
    • Export Citation
  • 26.

    Kovacs E, Das R, Wang Q, et al. Analysis of the role of the C-terminal tail in the regulation of the epidermal growth factor receptor. Mol Cell Biol 2015;35:30833102.

    • Search Google Scholar
    • Export Citation
  • 27.

    Kovacs E, Zorn JA, Huang Y, et al. A structural perspective on the regulation of the epidermal growth factor receptor. Annu Rev Biochem 2015;84:739764.

    • Search Google Scholar
    • Export Citation
  • 28.

    Siravegna G, Lazzari L, Crisafulli G, et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell 2018;34:148162.e7.

    • Search Google Scholar
    • Export Citation
  • 29.

    Azuma K, Tsurutani J, Sakai K, et al. Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun 2011;407:219224.

    • Search Google Scholar
    • Export Citation
  • 30.

    Hanker AB, Garrett JT, Estrada MV, et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin Cancer Res 2017;23:43234334.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1039 1039 27
PDF Downloads 587 587 27
EPUB Downloads 0 0 0